4 - AMPK, mTOR, and more... Flashcards
mTOR
-
PIKK (ser/thr kinase)
- that is expressed in ALL EUKARYOTIC organisms
- Mechanistic target of RAPAMYCIN
- responds to energy / AA / Oxygen levels
-
INSULIN induces mTOR signaling
- Regulates the regulation of energy
- Forms two complexes:
- mTORC1 = mtor + RAPTOR
- mTORC2 = mTOR + rictor
mTORC1 3 Major Functions
-
Activates Ribosomal Proteins
- S6K -> actively translating more proteins
- Induces the dissocation of 4E-BP1 from elF4E
- 4E-BP1 normally is inhibiting elF4E
- –> Initiates mRNA Translation
- Stimulates Protein Synthesis
- –> Initiates mRNA Translation
- 4E-BP1 normally is inhibiting elF4E
- Inhibits Catabolic process of _AUTOPHAGY_
Ultimately increases
Cell mass / size / proliferation
mTORC1 Activation pathway
-
Insulin Binding starts Signaling Cascade
- IRS-1 activates P13K
- Pip2-Pip3
- Activates PDK1
- Phosphoralates Ser/Thr AKT
-
Inhibits TSC1/2
- AMPK activates TSC
-
Inhibits RHEB conversion
- Activates mTORC1
-
Inhibits TSC1/2
- Phosphoralates Ser/Thr AKT
- Activates PDK1
mTORC1 initiation of cap-dependent mRNA Translation
- mTORC1 activation causes dissociation of 4E-BP1 from elF4E
- allows elF4FE complex to form
- binds to 7-mg CAP on 5’ end of mRNA
- -> Initiate cap dependent mRNA Translation
- binds to 7-mg CAP on 5’ end of mRNA
- allows elF4FE complex to form
Pathologies Associated With mTORC2
- Normally, PTEN** inhibits conversion of **P13K -> mTORC2
-
Cowden / Prostate CA / Endometrial CA / Giloblastoma
- All stop PTEN from inhibiting mTORC
- -> Turn ON TRANSLATION
- = Uncontrolled Growth
- -> Turn ON TRANSLATION
- All stop PTEN from inhibiting mTORC
-
Cowden / Prostate CA / Endometrial CA / Giloblastoma
PTEN / LKB1 / NF1 / VHL
- Proteins that are signaled by Oxygen/energy/hormones
- to INHIBIT mTORC1
- to CONTROL translation & Protein synthesis
- to INHIBIT mTORC1
- Various pathologies cause the Loss of the proteins
-
–> Activation of mTORC1
- -> Uncontrolled Growth / Cancer
-
–> Activation of mTORC1
Rapamycin
- pharmacological Inhibitor of mTOR
- Macrocyclic Lactone
- Induces Dimerization of mTOR / FKB12
- -> loss of signaling from interacting proteins
- Immunosuppresive Functions
Rapamycin Uses
-
Immunosuppresive Function
- blocks IL2 mediated T-cell proliferation
-
Prevent Restenosis in Coronary Stents
- potent inhibitor of vascular smooth muscle proliferation
- keeps vascular smooth muscle from growing around the stent
- potent inhibitor of vascular smooth muscle proliferation
- INHIBITS proliferation of many CANCER cells
Immunosuppressive Function of
Rapamycin = mTOR Inhibitor
- Normally mTOR allows for T-cell proliferation
- –> cell-cycle progression of IL-2 production
- -> Cascade of immunogenic events
- –> cell-cycle progression of IL-2 production
-
Inhibiting mTOR
-
-> blocks IL-2 activation of T / B Cells
- reduces the Immune Response
-
-> blocks IL-2 activation of T / B Cells
Prevention of Restenosis
Rapamycin = mTOR Inhibitor
- Restenosis = Inflammation of the area around the STENT
- Caused by the Proliferation of smooth muscle cells
-
mTOR Inhibition -> BLOCKS cell replication
- blocks muscle cell migration & proliferation of smooth muscle cells
Dual Effect of Rapalogs in Type 1 Diabetes
- Type 1 diabetes is treated by transplanting a pancreas or islet cells
- Inhibiting mTOR results in:
-
Preventing the rejection of beta islet cells
-
but hinder islet health
- b/c mTOR normally signals islet growth through S6K
-
but hinder islet health
-
Stopping the positive regulation of islet proliferation
- mTOR normally promotes islet proliferation
-
Preventing the rejection of beta islet cells
Rapalog
Rapamycin + its analogs
Alter PK/PD of Rapamycin
INHIBITS mTOR
Rapalogs in Type 2 Diabetes
- Rapamycin -> blocks S6K
- can help restore sensitivity
- S6K negatively inhibits Insulin receptors
- can help restore sensitivity
-
Sustained mTOR activation is one mechanism of INSULIN RESISTANCE
- from a reduction of downstream signaling of insulin receptor changes in phosphorylation
- can also degrade IRS2
- -> beta cell apoptosis
How does mTOR cause insulin resistance?
- Normally, Insulin or Glucose Binding
-
Activates mTORC1 -> S6K
-
S6K inhibits IRS insulin receptor
- = Normal Negative feedback
-
S6K inhibits IRS insulin receptor
-
Activates mTORC1 -> S6K
- In T2DM,
- Glucose + Obesity + Cytokines are constantly activating mTORC1
-
-> S6K is constantly inhibiting the insulin receptor
- -> INSULIN RESISTANCE
-
-> S6K is constantly inhibiting the insulin receptor
- Glucose + Obesity + Cytokines are constantly activating mTORC1
AMPK-5’
- Heterotrimeric Ser-Thr Kinase
- Senses DEPLETION of intracellular energy
- -> stimulates ATP GENERATION
- = Catabolic
- -> stimulates ATP GENERATION
- Senses DEPLETION of intracellular energy
- Allosterically activated by AMP
- Covalently modified by phosphorylation by LEPTIN
AMPK is activated by?
- Phosphorylation of Thr172 of the alpha subunit
- Catalyzed by:
- LKB1 or CaMKK2 (calcium)
- TAK1
-
KSR2
- directly acts on alpha, not Thr
- Catalyzed by:
- Directly activated @ Gamma subunit by:
- High AMP/ATP ratio (low energy)
- -> also blocks inhibition of AMPK thru PP2C-alpha
- High AMP/ATP ratio (low energy)
- EXERCISE
LKB1
Catayzes the phosphorylation on Thr172 on the alpha subunit
Activates AMPK
LKB1 is also a tumor suppresor
CaMKK2
CALCIUM
Catayzes the phosphorylation on Thr172 on the alpha subunit
Activates AMPK
Calcium dependent activation increases calcium
–> Increases activation of CaMKK2
TAK1
Catayzes the phosphorylation on Thr172 on the alpha subunit
-> Activates AMPK
TAK1 is always active
KSR2
Directly interacts with the alpha subunit
-> Activates AMPK
PP2C-Alpha
-
INHIBITS AMPK
- through inhibition of Thr172 phosporlation @ alpha
-
PP2C-alpha is Inhibited by:
- Increase in AMP/ATP ratio
AMPK is inhibited by?
-
CIDEA -> beta subunit
- Cell-death-inducing-like-effector-A
- PP2C-alpha -> Thr phosphorylation
CIDEA
INACTIVATES AMPK
- Forms complex w/ beta subunit of AMPK
- Mediates ubiquitin-dependent degradation
Metformin
INHIBITS mTOR
–> promising effects on cancer prevention
is a diabetes drug
AMPK on Lipid Metabolism
- Active AMPK -> Activates Catabolic Processes
-
fatty acid oxidation -> ATP
- Restore AMP/ATP ratio
-
fatty acid oxidation -> ATP
mTORC1 vs mTORC2
-
mTORC1
- RAPTOR
- Most used in signal transduction
- mTORC2
- rictor
- MAIN DIFFERENCE IS THE PROTEIN COMPLEX
How does AMPK inhibit mTOR?
- AMPK phosphorylates TSC2
-
Activation of TSC leads to RHEB conversion
- -> Inhibition of mTOR signaling
-
Activation of TSC leads to RHEB conversion
-
TSC normally inhibits RHEB conversion
* which activates mTOR signaling
-
TSC normally inhibits RHEB conversion
What activates mTOR?
-
Insulin / IGF
- -PTEN
- AMINO ACIDS
-
Mitogens
- -NF1
-
High Energy
- -LKB1
-
Oxygen
- -VHL
- P13K activation